Breaking AI & Tech News Analyzed

President Donald Trump signed an executive order on Saturday in the Oval Office, joined by podcaster Joe Rogan, to fast‑track the federal review of psychedelic drugs such as ibogaine, aiming to broaden treatment options for serious mental illness.The ceremony highlighted Rogan’s long‑standing advocacy for ibogaine, a plant‑derived compound used by some veteran groups to address post‑traumatic stress. Rogan recounted texting Trump about the drug, to which the president replied, “Sounds great. Do you want FDA approval? Let’s do it.”Trump framed the order as a lifeline for patients: “Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life.” He added that successful outcomes could have “a tremendous impact.”In a brief moment of levity, Trump joked, “Can I have some, please? I’ll take some.” He quickly refocused, noting he has no time for depression and stays busy instead.The move enjoys rare bipartisan backing, despite ibogaine and other psychedelics remaining classified under the federal government’s most restrictive drug schedule.Health Secretary Robert F. Kennedy Jr. had previously pledged to ease medical access to psychedelics, a stance echoed in the new order, which directs the Department of Health and Human Services to allocate at least $50 million to states developing programs for serious mental‑health conditions.Simultaneously, the FDA is set to issue “national priority” vouchers for three psychedelic candidates. Commissioner Marty Makary said the vouchers will enable rapid approval “if they align with our national priorities.”The agency also plans the first human trials of ibogaine in the United States, overcoming earlier concerns about potential fatal heart effects.Ibogaine’s origins trace back to the Bwiti religious ceremonies in West‑Central Africa, where the plant has been used for centuries in spiritual contexts.Former Navy SEAL Marcus Luttrell, also present at the event, praised ibogaine, stating, “It absolutely changed my life for the better.”Rogan’s endorsement and the executive order have added a new dimension to Trump’s 2024 campaign narrative, even as he has publicly questioned the administration’s stance on the war with Iran.

After serving in Afghanistan, Army Ranger Jesse Gould developed PTSD and turned to drinking to cope. Seeking an alternative to lifelong medication, Gould discovered psilocybin in Peru, which significantly alleviated his symptoms.Gould founded the Heroic Hearts Project, a non-profit hosting ayahuasca and psilocybin retreats for veterans. The organization has helped over 1,500 veterans and their spouses without any psychotic episodes.State lawmakers are taking notice of psilocybin's potential health benefits, with Colorado, New Mexico, and Oregon legalizing it for therapeutic use. At least eight states are considering similar legislation, despite some arguing that the FDA should approve it first.Research suggests psilocybin can be safe and effective when administered with psychological support. A 2025 study found it was associated with symptomatic improvement in adults with PTSD. Clinical psychologist Joseph Zamaria notes that psilocybin can disrupt the brain's default mode network, allowing people to detach from harmful narratives.However, some experts, like Albert Garcia-Romeu, are skeptical about state-led legalization without FDA approval, citing potential unknown risks. Gould counters that the suicide rate among veterans is a pressing issue, with 35 deaths per 100,000 people in 2023, more than double the general population's rate.

The U.S. Food and Drug Administration announced on Wednesday that it has granted expedited approval to Eli Lilly’s oral weight‑loss medication, orforglipron—marketed under the brand name Foundayo. This makes Foundayo the second GLP‑1 pill to reach U.S. consumers, following Novo Nordisk’s Wegovy tablet approved in December. Orforglipron works by mimicking a natural hormone that regulates appetite and satiety, offering a non‑injectable alternative to existing GLP‑1 injectables. David A. Ricks, Eli Lilly’s chair and CEO, highlighted that fewer than one in ten eligible patients are currently using GLP‑1 therapies, citing barriers such as cost, stigma, and perceived complexity. Unlike Wegovy, which must be taken on an empty stomach each morning, Foundayo can be taken anytime of day regardless of meals, simplifying dosing schedules. Patients will start on a low dose that is gradually increased to mitigate side‑effects. Pricing is projected at $149 per month for the initial dose, with higher‑strength formulations potentially reaching $349 monthly. While private‑insurance coverage remains uncertain, a Trump‑administration proposal could allow Medicare to cover certain patients as early as this summer, with copayments as low as $50 per month. Distribution will commence on Monday through LillyDirect’s direct‑to‑consumer channel, with broader availability in pharmacies and telehealth platforms expected shortly thereafter. The convenience of a once‑daily pill is anticipated to improve adherence, especially for individuals who avoid injectables due to needle aversion or rigid dosing requirements. The approval follows a fast‑track submission submitted only months ago, positioning Foundayo to enter the market roughly three months after Wegovy. This rapid rollout is set to intensify competition in the burgeoning GLP‑1 space, where new agents are continually emerging with claims of better efficacy and lower costs.

Robert F Kennedy Jr, the US health secretary, has unveiled a chaotic and unpredictable agenda for public health policy under his 'Make America Healthy Again' (Maha) initiative. His approach tends to favor personal choice and autonomy over large-scale, mandatory public health interventions, such as childhood vaccine requirements.The Maha agenda has raised concerns over the potential risks associated with injectable peptide drugs. Mr. Kennedy plans to open up the sale of 'about 14' of these drugs to the public, despite the US Food and Drug Administration (FDA) restricting 17 peptides in 2023 due to 'potential significant safety risks'. None of these peptides have been proven to be safe or effective for human use.The peptides in question are often promoted for biological enhancement, such as increasing muscle mass or cognitive benefits, but the evidence for these effects in humans is thin. Reports of people self-administering peptide therapies, usually bought from China 'for research use only', are widespread, particularly in Silicon Valley.The Maha project wants to make the grey market the only market, effectively sanctioning mass public use of unproven treatments. Peptides are clearly drugs and shouldn’t be allowed for widespread use without rigorous clinical trials. Opening loopholes for sale would undermine the precautionary principle that has successfully led public health policy for generations.It is also worth noting that other governments are unlikely to be as cavalier as Mr. Kennedy about peptides. However, people everywhere will continue to call for more personal choice and more bodily autonomy, and those conversations are important. The case for safety, proof, and regulation must be made to ensure that public health policy prioritizes the well-being of individuals.